What's Happening?
Dr. Jennifer Guerriero, an assistant professor at Brigham and Women’s Hospital in Boston, has been awarded the Cancer Research Institute (CRI) Lloyd J. Old STAR award for her innovative work in cancer immunotherapy. Dr. Guerriero's research focuses on engineering
a patient's own monocytes with a chimeric antigen receptor (CAR) to target and eliminate TREM2-positive macrophages within tumors. These specific macrophages are known to suppress immune responses and prevent T cells from effectively attacking cancer. Her approach aims to clear these suppressive cells, thereby allowing T cells to better infiltrate and activate against the tumor. This strategy differs from traditional CAR T-cell therapy, which directly targets cancer cells. Early studies in mice have shown promising results, including tumor shrinkage, improved survival, and enhanced T-cell activation.
Why It's Important?
Dr. Guerriero's research represents a significant advancement in the field of immunotherapy, particularly for solid tumors where current immunotherapies often fall short. By focusing on the tumor microenvironment rather than directly on cancer cells, her work addresses a critical barrier to effective treatment: the immune-suppressive nature of certain macrophages. This novel approach has the potential to make existing immunotherapies, such as CAR T-cell therapy, more broadly effective across a wider range of cancers. The CRI Lloyd J. Old STAR award is crucial for funding this 'first-in-class' therapy, which might struggle to secure traditional funding due to its innovative and unproven nature. Success in this area could lead to new treatment paradigms, offering hope to patients who do not respond to current immunotherapies and significantly improving survival rates for various solid tumors.
What's Next?
With the STAR funding, Dr. Guerriero plans to further investigate the safety and effectiveness of her engineered monocytes. Her immediate next steps include refining the engineered cells and working towards developing a clinical-grade product suitable for human trials. This will involve expanding her research program, hiring additional team members, acquiring necessary materials, and fostering collaborations beyond her institution. The long-term goal is to translate these promising preclinical findings into a viable clinical therapy. Given that TREM2-positive macrophages are found across multiple solid tumors, the implications of her work could extend beyond a single cancer type, potentially offering a broad-spectrum approach to overcoming immunotherapy resistance.
Beyond the Headlines
Dr. Guerriero's project highlights the vital role of philanthropic and specialized institutional funding, like the CRI STAR program, in supporting high-risk, high-reward scientific endeavors. Such funding mechanisms are essential for pioneering research that may not fit conventional funding criteria but holds the potential for transformative breakthroughs. The concept of 'Scientists Taking Risks' (STAR) underscores the need for an ecosystem that encourages bold, unconventional scientific exploration. This research also delves into the complex interplay between different immune cells within the tumor microenvironment, suggesting a more nuanced understanding of cancer immunology is emerging. This could lead to a new generation of immunotherapies that are more sophisticated in their targeting and less prone to resistance, ultimately changing the landscape of cancer treatment and patient care.
